Monday, October 2, 2023
Monday, October 2, 2023

Contact: 561.316.3330

Conavi Medical Plans for Strategic Expansion in U.S. Market

Conavi Medical Inc., a leader of hybrid imaging guidance for common minimally invasive heart procedures, plans to expand the presence of its Novasight Hybrid System in the U.S. market in 2022 under the guidance of its new leadership team.

Thomas Looby, chief executive officer, Conavi Medical, appointed in April of 2021 to focus on the company’s strategic growth plans, has set the U.S. market as the company’s near-term focus. Looby’s extensive background in leading medical device companies and developing global markets for cutting-edge technology bolsters the leadership team as they prepare for new milestones. To efficiently execute this expansion, Robert Skidmore joined as vice president of Operations in October 2021 to scale up production to meet the expected demand.

“The Conavi team is aligned on a cohesive plan to introduce and drive the value proposition of our innovative system to select early adopters and luminaries in the U.S.,” said Looby. “Our recently raised capital leaves us well positioned for operational growth. We are already ramping up manufacturing and expanding our U.S. based clinical team to support our customers.”

The Novasight Hybrid System is a new imaging platform for use by interventional cardiologists during common minimally invasive heart procedures. This patented technology is the first and only clinical system that enables simultaneous and co-registered imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT).

Dr. Brian Courtney, chief medical officer and co-founder, Conavi Medical, said, “The clinical practice guidelines for intravascular imaging were recently updated to reflect clinical data on how intravascular imaging can improve clinical outcomes for angioplasty procedures.   This is an important step in increasing the use of advanced imaging in North America.” He added, “We believe hybrid imaging with IVUS and OCT will have an important role in clinical, research and educational applications.”

Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration, and regulatory approval for clinical use from Health Canada, and the Ministry of Health, Labor and Welfare (MHLW) in Japan.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


Broken String Biosciences Strengthens Senior Leadership Team

Bringing significant expertise in their respective fields, Vincent Smith, PhD and Jessica Rich appointments are a key part of Broken String’s strategy to deliver on its Series A goals, which include the continued development of its INDUCE-seq™ DNA break-mapping platform and acceleration of its commercial expansion across global markets.

New Chief Sales Officer at Encare with Focus on Continued Global Expansion

The HealthTech company Encare has recruited Lotta Sellén as the new Chief Sales Officer (CSO). Lotta Sellén has solid experience in the pharmaceutical, healthcare and HealthTech industries.

CorWave Appoints Magalie Durrèche as Chief Financial Officer

Magalie Durrèche will oversee the financial management and participate in the strategic planning and fundraising of CorWave, a company developing and manufacturing a blood pump based on breakthrough technology. She succeeds Zina Hamoumi, who served as Chief Financial Officer for five years before deciding to focus on other projects.

Veracyte Names Dr Phillip G Febbo Chief Scientific Officer and Chief Medical Officer

“Phil G Febbo is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support,” said Mr. Stapley. “His experience and expertise will be critical to further enhancing our ability to serve our customers and, ultimately, to transforming cancer care for patients all over the world.”

GrayMatters Health Expands US Executive Team, Including Appointment of Dr Aron Tendler as Chief Medical Office

Dr Aaron Tendler is a board-certified psychiatrist based in Palm Beach, Florida, bringing over 20 years of experience as an industry leader researching novel treatments for mental health disorders.

By using this website you agree to accept Medical Device News Magazine Privacy Policy